By Bloomberg Published May 29, 2024 Abercrombie & Fitch Co. blew past sales estimates in the first quarter and raised its year outlook, extending a remarkable comeback from the teen fashion graveyard. Shares of the retailer jumped by 3% in premarket trading in New York. Revenue rose for the sixth straight quarter to $1 billion. [...]read moreAbercrombie sales are rising even faster than analysts expected
Dr Martens releases its latest results this week (30 May) and analysts are expecting a tough-to-read report with profit down sharply and revenue down too as the giant US market remains weak for the brand. Dr Martens With the firm having delivered a profit warning last month, they’re expecting turnover to be under £900 million, [...]read moreAnalysts expect Dr Martens to report profits plunge this week
Isaac Boltansky, managing director and director of policy research at BTIG, said on Tuesday that he does not believe “a second Biden administration is going to move quickly towards” addressing some technical issues to end the GSEs’ conservatorship. In his opinion, the Biden administration may focus on initiatives to improve affordability, which may increase demand [...]read moreWith elections ahead, housing policy analysts discuss the end of GSEs’ conservatorship
United Wholesale Mortgage’s (UWM) revenue margins “don’t stand out like” one would expect if the company was overcharging borrowers, analysts at BTIG said on Monday. The comments follow a Hunterbrook Media report from last week stating that UWM pressures brokers to send loans its way, resulting in higher costs to customers. “We think the premise of the thesis [...]read morePremise of the Hunterbrook Media thesis on UWM is ‘misplaced:’ BTIG analysts
Analysts at investment bank Keefe, Bruyette & Woods believe that the Department of Justice will intervene in Sitzer/Burnett commission lawsuit after receiving the green light to reopen its investigation into the National Association of Realtors. In a note published on Sunday, the analysts wrote that thanks to this “favorable judgement, the DOJ is now unconstrained [...]read moreDOJ will intervene in NAR’s commission lawsuit settlement: KBW analysts
Analysts had mixed views of H&M Group’s latest results this week, some emphasising how the company still had plenty of work to do. But investors in the firm didn’t seem to be listening to those at the gloomier end of the spectrum and sent its share price up over 15% on Thursday. It jumped again [...]read morehere’s what the analysts think
UBS analysts are predicting Netflix will raise streaming plan prices in 2024, according to Variety. This price hike prediction follows announcements made alongside the company’s fourth-quarter results in January, which hinted at such incremental increases in Netflix’s subscription plans. “We expect to see rate increases [from Netflix] this year,” UBS analyst John Hodulik said, pointing [...]read moreNetflix May Rise Prices Again This Year Analysts Expect
Image: Sony While the PlayStation 5 is apparently entering the later stages of its life cycle, some industry analysts think Sony might be planning to give the system an update similar to the one the PS4 received with the PlayStation 4 Pro within the next year. Thank You, PS Plus, For Making My Backlog Even [...]read morePS5 Pro Likely Launching Ahead Of GTA 6, Analysts Say
Analysts are predicting a PS5 Pro might enter the market soon, possibly as a way to boost interest in the console brand and have a more powerful platform ready for the release of Grand Theft Auto 6. “There seems to be a broad consensus in the game industry that Sony is indeed preparing a launch [...]read morePS5 Pro Could Launch Just In Time For GTA 6, Analysts Predict
CASE PREVIEW By Amy Howe on Jan 9, 2024 at 2:52 pm The court will hear oral argument in Smith v. Arizona on Jan. 10. (Abbie Fitz via Shutterstock) Jason Smith claims that when an expert witness testified in Arizona’s drug possession case against him using drug analysis performed by a former state employee, it [...]read moreJustices to hear cross-examination dispute over drug analyst’s testimony